Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Empower Clinics Inc EPWCF

Empower Clinics Inc. is a Canada-based integrated healthcare and medical device company with multi-disciplinary clinics. The Company provides body and mind wellness for patients through its medical clinics, digital and telemedicine care, medical diagnostics laboratories, and sale of medical devices. Its segments include Health & Wellness, comprising clinic operations, patient visits, and telemedicine services; Diagnostics & Technology, comprising the diagnostic testing services provided by Kai Medical, and the sale of medical equipment by Kai Medical Canada Corp. and MediSure; and Corporate. It is focused on offering clinical trial services, such as clinical trial design, patient recruitment, data management and regulatory compliance for the pharmaceutical, biotechnology and medical device industries. It has two clinical research sites in Dallas, Texas, becoming a site management organization (SMO) with six principal investigators (PI) with multiple clinical trials under application.


GREY:EPWCF - Post by User

Post by Ergarets12on Dec 10, 2020 10:06am
114 Views
Post# 32076053

Developing a Treatment

Developing a Treatment
 
 
Relapse is still a common scenario in acute myeloid leukemia (AML) treatment and occurs in approx 40-50% of younger and the great majority of elderly patients. The prognosis in relapsed AML patients is generally poor but depends largely on the timing of relapse (early versus late) and the possibility of allogeneic hematopoietic stem cell transplantation (HSCT).
 
In AML patients relapsing after HSCT and good performance status, intensive therapy can be considered with subsequent cellular therapy such as donor lymphocyte infusion (DLI) or a second HSCT. However, less than approx 20% of these patients are alive after 5 years. For those patients that are unfit, the therapeutic aim is to prolong life with acceptable quality of life.
 
With this development treatment for leukemia patient would you support? Check disclaimer on profile
<< Previous
Bullboard Posts
Next >>